New York, USA – October 8, 2024 – Recent breakthroughs at the ESMO Congress 2024 in Barcelona, showcasing the promising potential of oncolytic viruses (OVs) in treating various cancers, including advanced melanoma, have further ignited interest in this innovative therapy. These engineered viruses, designed to infect and destroy tumor cells selectively, represent the forefront of cancer immunotherapy. As oncolytic virus therapy continues to gain momentum, leading biotech firms like Creative Biolabs are stepping up with unparalleled expertise and tools to advance research and therapeutic development in this area.
“Oncolytic virotherapy is no longer a distant dream. It’s rapidly becoming one of the most exciting developments in the fight against cancer. By genetically engineering viruses, scientists can create a therapy that not only halts cancer growth but also stimulates the body’s immune system to mount a stronger defense.” A scientist from Creative Biolabs says so.
But while the science is advancing, bringing these therapies from the lab to the clinic requires robust support systems—this is where Creative Biolabs comes in. Known for their all-encompassing services in the field of oncolytic virus therapy, they provide essential tools and expertise to help scientists and pharmaceutical companies bridge the gap between research and real-world application.
One of the key offerings of Creative Biolabs’ offerings is oncolytic virus construction that assists researchers in building customized OVs by introducing specific transgenes into viruses. This is no small feat—these modifications make the viruses highly specialized, allowing them to target and destroy cancer cells while leaving healthy cells intact. The oncolytic adenovirus construction kit and pre-made oncolytic viruses offered by Creative Biolabs make it easier than ever for labs to develop and test these therapies.
“Whether it’s adenoviruses, herpesviruses, or vesicular stomatitis viruses, we have the tools to ensure that researchers can create the ideal OV for their projects.” The scientist elaborates.
Adding to the momentum, a September publication in AACR titled “A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers” underscores OV therapy’s growing importance in the fight against cancer. Creative Biolabs, in addition to helping scientists build OVs, also excels in developing disease-specific oncolytic virotherapies, by tailoring their solutions to the unique challenges of each type of cancer. Such personalized touch makes a significant difference when treating heterogeneous diseases such as melanoma, breast cancer, or glioblastoma.
Beyond technical expertise, Creative Biolabs brings a consultative approach to their clients, providing insights and recommendations based on the latest research and clinical trials.
“We’re not just a vendor—we’re a partner in innovation, walking hand in hand with our clients to overcome the hurdles that inevitably arise in cutting-edge scientific research. From concept to construction to clinical translation, Creative Biolabs covers every base.” The scientist says.
For more information, visit Creative Biolabs’ official page at https://www.creative-biolabs.com/oncolytic-virus.
About
As the field of oncolytic virotherapy continues to evolve, Creative Biolabs is positioning itself as the go-to resource for anyone serious about harnessing the power of viruses to treat cancer. Their comprehensive suite of services not only streamlines the development process but also enhances the likelihood of success in next stage trials. For the rest of 2024, a team of dedicated scientists will show up at the forthcoming industry exhibitions to share the latest advancements in biotech with peers.
* October 22nd, BioPharma Drug Discovery Nexus Conference
* November 4th, Annual World ADC San Diego
* December 15th, Antibody Engineering & Therapeutics (US) 2024
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/oncolytic-virus
